A bet on this Canadian marijuana company is a bet on the political future of the country south of its home market.
These three biotech stocks could be great buys this month.
Acadia's stock has taken flight this year.
Investor concerns over the competitive outlook for the company's Pompe disease therapy candidate weighed on its stock price.
Amgen's best-selling medicine is safe from biosimilar competition for now.
Dynavax's stock surged higher in August. Can this small-cap biotech keep churning higher?
Acadia's flagship drug notched a key late-stage win today.
Biotech stocks tend to react badly to advisory committee meetings.
The biotech rivals each aim to dominate the treatment market for non-alcoholic steatohepatitis (NASH).
Patent cliffs and pipeline risks are among the reasons these biologic drug specialists are attractively priced today.
Retrophin's PKAN drug candidate missed the mark in a late-stage trial.
These three health care stocks deserve your undivided attention right now.
These three diabetes-oriented companies should be on your radar right now.
A surprise rejection is weighing on Sarepta's shares today.
Novavax's RSV vaccine may not be dead after all.
The FDA will hold an advisory committee meeting after all.
Its high-profile DMD gene-therapy candidate hit an unexpected stumbling block.
Catalyst's shares took a sizable hit this morning.
Glaukos makes a bid for Avedro in an all-stock transaction.
Canopy Growth, Charlotte's Web Holdings, and HEXO Corp. are worth checking out this month. Here's why.